The use of short-term high-dose atorvastatin pretreatment is safe and significantly improves the final TIMI flow grade as well as reduces the 30-day MACEs in ACS patients post-PCI. This finding encourages the use of short-term high-dose atorvastatin pretreatment as an alternative for ACS patients undergoing PCI, but more high-quality randomized clinical trials are still needed to confirm the long-term efficacy and safety.
Monday, January 12, 2015
Short term high dose statin use in acute coronary syndrome
From a recent meta-analysis:
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment